San Diego Compounding Pharmacy, San Diego, CA

Is San Diego Compounding Pharmacy registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does San Diego Compounding Pharmacy hold a California pharmacy license?

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones.

Has San Diego Compounding Pharmacy had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jul 8, 2019), 1 state referral letter (Jul 8, 2019) and 1 FMD-145 letter (Jul 8, 2019) for San Diego Compounding Pharmacy. State board actions: no California State Board of Pharmacy action under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
San Diego Compounding Pharmacy
Location
San Diego, CA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Jul 8, 2019
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 1 published Form 483
Form 483 text on this page
2 Form 483s, 4 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as San Diego Compounding Pharmacy, a 503A facility, with 3 dated actions.

Document
Jul 8, 2019Warning letter close-outWarning Letter Close Out Issued 07/08/2019Not linked by FDA
Jul 8, 2019FMD-145 letterFMD-145 Letter Issued 07/08/2019FDA copy (archived)
Jul 8, 2019State referral letterReferral Letter to the California State Board of Pharmacy Issued 07/08/2019fda.gov

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists San Diego Compounding Pharmacy, San Diego, CA (FEI number 3006072852), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Oct 25, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30060728521069745
Nov 15, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3006072852997047

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 4 numbered observations in all, across 2 inspections ending Dec 23, 2016 to Oct 25, 2018. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Oct 17, 2018 to Oct 25, 2018: 1 observation

Firm on the cover
San Diego Compounding Pharmacy, 5395 Ruffin Rd Ste 104, San Diego, CA 92123-1338
FEI number
3006072852
Establishment type on the cover
Producer of non -sterile drug products This document li sts observations made by the FDA representative(s) during the inspection of your facility . They are inspectional observations, and do not represent a final Agency determination regarding your compliance. lf you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, equipment and utensils are cleaned; however, hazardous drugs were produced without providing adequate cleaning of work surfaces and utensils in that the use of a cleaning agent to inactivate any residues of hazardous drug material is not employed, which could potentially affect the safety, identity, strength, quality or purity of drug products manufactured using shared equipment.

For example, the firm produces products such as BI-EST 5.SMG/GM HRT CREAM which involves the weighing of Estradiol in a hood. The firm's current cleaning includes only the use of <Redacted B4>

Inspection dated Dec 23, 2016 by FDA (dates on the form not read): 3 observations

Firm on the cover
San Diego Compounding Pharmacy, 5395 Ruffin Rd., Suite 104, San Diego, CA 92123
FEI number
3006072852
Establishment type on the cover
Producer of non-sterile and sterile drug products THIS DOCUMENT LIST S OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN ODSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION IMT H THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT T HE PHONE NUMBER AND ADDRESS ABOVE.
FDA district office on the cover
Los Angeles District 19701 Fairchild Irvine, CA 92612
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The <Redacted B4> not always conducted for each lot of sterile drug products. Sterile drug products are produced by the firm from non-sterile API via <Redacted B4> under aseptic processing. There is <Redacted B4> sterilization offinished drug products. The firm does not always conduct <Redacted B4> used to produce sterile drug products.

For example, Testosterone Cypionate 200mg/mL, Lot# 06/16/2016:0816 was produced via <Redacte d B4 > and aseptic proces sing. There was no evidence that testing was conducted to <R ed acted B4> During the inspec tion, the firm discontinued the production of sterile drug products indefinitely.

Observation 2

The firm has not demonstrated that the aseptic filling and closing operations are a dequate to produce sterile drug products. Specifically, there have been no media fill process simulations performed in the firm's cleanroom and ISO Class 5 Hood. During the inspection, the firm discontinued the production of sterile drug product indefinitely.

Observation 3

Room air pressure differentials are not monitored during each production ofaseptically processed sterile drug products. The firm's cleanroom suite and ISO Class 5 Hoods used to produce sterile drug products lack gauges or other devices to measure and/or monitor the air pressure differentials. Air pressure differentials are only measured and recorded <Redacted B4> During the inspection, the firm discontinued the production of sterile drug products indefinitely.

J 1

State board of pharmacy records

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.